- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07270575
Resorberbara Stödstrukturer med everolimus-Eluering för Behandling av Infrapopliteal Artärsjukdom hos Patienter med Kronisk Livshotande Ischemi i Extremitet (RESCUE)
Resorberbara Scaffolds med everolimus-Eluering för Behandling av Infrapopliteal Artärsjukdom hos Patienter med Kronisk Livshotande Ischemi i Extremitet
RESCUE is a Europe-wide study that will follow 400 people with critical limb-threatening ischemia (CLTI). It aims to see how well Esprit BTK™ Everolimus Eluting Resorbable Scaffolds work in real-life medical settings. The study focuses on people who have heavily calcified arteries in the infrapopliteal areas of the leg.
These drug-eluting resorbable scaffolds release a medication that helps prevent the inner wall of the blood vessel from thickening after injury or surgery. This can reduce the chance of the artery becoming blocked again (a problem called restenosis), while also giving temporary structural support to the vessel. Over time, the scaffold naturally dissolves in the body, which may lower the long-term risks associated with permanent metal stents.
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Claire Poulet, PhD
- Telefonnummer: +41 79 385 16 78
- E-post: oracue@cirse.org
Studera Kontakt Backup
- Namn: Dhwani S. Korde, PhD
- Telefonnummer: +4367762942469
- E-post: oracue@cirse.org
Studieorter
-
-
-
Hull, Storbritannien, HU3 2JZ
- Rekrytering
- Hull University Teaching Hospitals NHS Trust
-
Huvudutredare:
- Raghu Lakshminarayan, Dr
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Adult CLTI patients treated with the Esprit BTK everolimus-eluting resorbable scaffold following adequate vessel preparation for infrapopliteal artery disease.
Beskrivning
Inclusion Criteria:
- Rutherford classification category ≥4;
- Treatment of infrapopliteal lesions with the Esprit BTK everolimus eluting resorbable scaffold system following adequate vessel preparation;
- Calcification of target lesions must be visible on fluoroscopy or CT-angiography;
- Patients competent and willing to provide informed consent.
Exclusion Criteria:
- Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);
- Inadequate inflow (>30% stenosis) following optimization;
- Insufficient direct outflow (less than 1 run-off vessel);
- Endovascular procedure(s) on the treatment site within 4 weeks before index procedure;
- Patients planned to receive an above ankle amputation of the target limb;
- Patients enrolled in ORACLE (ClinicalTrials.gov ID NCT07270562).
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Adult CLTI patients with infrapopliteal calcified lesions
Adult CLTI patients planned to receive the Esprit BTK™ resorbable scaffold following pre-dilatation with angioplasty balloon. |
The Esprit BTK™ is a bioresorbable vascular scaffold designed for arteries below the knee. It provides temporary support to keep the vessel open while releasing everolimus-an antiproliferative drug that helps prevent excessive tissue growth and reduces the risk of restenosis. As the scaffold delivers the medication, it gradually dissolves, potentially lowering long-term risks associated with permanent stents.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of lesions free from Clinically-Driven Target Lesion Revascularization (CD-TLR)
Tidsram: 12 months
|
Defined as freedom from any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion. |
12 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
CD-TLR-free survival per target lesion
Tidsram: Until the end of the follow-up period of 3 years
|
Defined as the time between first index procedure and any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion. |
Until the end of the follow-up period of 3 years
|
|
Clinical response using Rutherford classification categories
Tidsram: 12, 24, and 36 months
|
The Rutherford classification is a clinical scale used to categorize the severity of peripheral arterial disease: Category 0 = asymptomatic; Category 1 = mild claudication; Category 2 = moderate claudication; Category 3 = severe claudication; Category 4 = ischemic rest pain; Category 5 = minor tissue loss; Category 6 = severe tissue loss. |
12, 24, and 36 months
|
|
Wound status
Tidsram: 12, 24, and 36 months
|
Defined as healing status of the dominant ischemic wound of the target limb (complete, partial, unchanged, worsening). |
12, 24, and 36 months
|
|
Freedom from major amputation of the target limb
Tidsram: 12 and 24 months
|
Defined as absence of any amputation of the target limb (above ankle). |
12 and 24 months
|
|
Amputation-free survival
Tidsram: Until the end of the follow-up period of 3 years
|
Defined as time between first index procedure and amputation of the target limb, minor (digital, metatarsal), major below the knee or major above the knee (excluding any amputation planned before the index procedure). |
Until the end of the follow-up period of 3 years
|
|
Overall survival
Tidsram: Until the end of the follow-up period of 3 years
|
Defined as the time between the first index procedure and death of any cause. |
Until the end of the follow-up period of 3 years
|
|
Patient-reported health-related quality-of-life
Tidsram: Baseline, Day 0 (day of procedure), 6-, 12-, 24-, 26-months post treatment
|
Measured by Vascular Quality of Life Questionnaire - 6 items (VascuQol-6), which is a short patient-reported outcome measure (PROM), used to assess health-related quality of life in people with PAD. It consists of 6 questions, each scored from 1 to 7, with 1 as the worst possible quality of life and 7 as the best possible quality of life. Higher overall scores reflect better quality of life for patients with PAD. |
Baseline, Day 0 (day of procedure), 6-, 12-, 24-, 26-months post treatment
|
|
Frequency and severity of procedural complications and other adverse events
Tidsram: Within 30 days after the index procedure
|
Grading according to the classification system of the Cardiovascular and Interventional Radiological Society of Europe. |
Within 30 days after the index procedure
|
|
Frequency of major adverse limb events (MALE) and peri-operative death (POD).
Tidsram: 6 months for MALE; Within 30 days after the index procedure for POD
|
MALE include above-ankle amputation in the index limb, major re-intervention on the index limb at 6 months and POD includes perioperative (30-day) mortality. |
6 months for MALE; Within 30 days after the index procedure for POD
|
|
Clinical response using ankle-brachial index (ABI)
Tidsram: 12, 24, and 36 months
|
The ankle-brachial index (ABI) is a non-invasive measure calculated as the ratio of systolic blood pressure at the ankle to systolic blood pressure at the arm. ABI categories commonly used to classify peripheral arterial disease are: >1.40 = non-compressible arteries; 1.00-1.40 = normal; 0.91-0.99 = borderline; 0.41-0.90 = mild to moderate peripheral arterial disease; <0.40 = severe peripheral arterial disease. |
12, 24, and 36 months
|
|
Clinical response using toe pressure
Tidsram: 12, 24, and 36 months
|
The toe pressure test measures distal limb perfusion by recording systolic pressure at the toe. In CLTI patients, toe pressure ≤30 mmHg is commonly used to indicate severe ischemia, while values >30 mmHg suggest better perfusion. |
12, 24, and 36 months
|
|
Clinical response using WIfi (wound, ischemia and foot infection) score
Tidsram: 12, 24, and 36 months
|
The WIfI classification is a staging system used to assess CLTI based on wound extent, ischemia severity, and foot infection. Each component is graded from 0 (none) to 3 (severe). Lower WIfI scores indicate a lower risk of limb loss and a lesser urgency for revascularization, whereas higher scores indicate greater disease severity, higher amputation risk, and greater potential benefit from revascularization. |
12, 24, and 36 months
|
|
Restoration of normal lumen per target lesion
Tidsram: Immediately upon procedure completion
|
Defined as residual stenosis ≤30%, immediately after completion of full planned procedure. |
Immediately upon procedure completion
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Studiestol: Gerd Grözinger, Prof. Dr. med., SLK Kliniken Heilbronn GmbH
- Studiestol: Marianne Brodmann, Univ.-Prof. Dr. med., Medizinische Universität Graz
- Studiestol: Raghu Lakshminarayan, Dr, Hull University Teaching Hospital
- Studiestol: Stefan Müller-Hülsbeck, Prof. Dr. med., DIAKO Krankenhaus gGmBH
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
- Perifer artärsjukdom
- CLTI
- Infrapopliteala artärer
- Kritiskt livshotande ischemi i extremitet
- Infrapopliteal artärsjukdom
- Esprit BTK Everolimus-befriande upplösningsbar stent
- Läkemedelsavgivande resorberbar stent
- Resorberbart kärlscaffold
- Studie med verklighetsbaserade data
- Patienter med infrapopliteal sjukdom
- Förkalkade perifera artärlesioner
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- RESCUE
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .